Eric Cantor named president and CEO of PhRMA
The former House majority leader will lead the pharmaceutical lobbying group.
AI-assisted coverage comparison, editor-supervised · How this was made
Speaker Johnson Hosts Portrait Unveiling Ceremony Honoring Former Speaker Kevin McCarthy
Photograph: Common Dreams (embedded from source)
What this story says
- Former US House Majority Leader Eric Cantor has been named president and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA).
- PhRMA spent $38 million on lobbying efforts, according to reports.
- Peter Maybarduk of Public Citizen criticized Cantor's past legislative record on drug prices.
- Cantor received approximately $900,000 from the pharmaceutical and health product industry during his time in Congress.
Who covered it
Percentages are shares of the 9 outlets carrying a published leaning rating. 2 of the 11 outlets we know ran this story carry no rating and are not counted in them. Coverage measured .
Trust
42/100
Craft
57/100
Hype
41/100
11 sources · methodology
Thin on the left so far
Only 1 of the 9 outlets with a published leaning rating that ran this story are rated left.
This story is still being watched, so it is a count and not yet a finding. Coverage keeps arriving for hours after an event, and a side that has published nothing this morning may publish by tonight. If it is still true when we stop checking, we will say so plainly.
Eric Cantor, former US House Majority Leader, has been appointed president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA). PhRMA is a lobbying group for the pharmaceutical industry. Cantor served in the US House of Representatives from 2001 to 2014, holding the position of House majority leader from 2011.
The appointment comes at a time of significant public concern over the cost of prescription drugs. PhRMA has been actively lobbying on these issues, having spent $38 million on lobbying efforts, according to reports. The organization stated that Cantor's experience makes him suitable to lead during a critical period for the industry.
Critics have raised concerns about Cantor's past legislative record. Peter Maybarduk, director of access to medicines at Public Citizen, stated that Cantor has a history of legislating in favour of corporations over working families. During his congressional tenure, Cantor received approximately $900,000 from the pharmaceutical and health product industry. Reports indicate he voted against legislation aimed at lowering prescription drug costs, including measures to allow importation of lower-cost drugs and to enable federal negotiation of Medicare drug prices.
Coverage comparison
What the coverage left out
None of the right-rated digests mention the $38 million PhRMA spent on lobbying efforts. None of the centre-rated digests mention the $38 million PhRMA spent on lobbying efforts or the specific criticisms of Cantor's past legislative record regarding drug prices.
Still developing. We have re-checked which outlets are covering this 3 times, most recently on 29 Sept 2026, 23:00, and will add the sides that appear.
How each side covered it
Our own reading of the reporting listed below, written from the outlets’ articles rather than quoted from them. The reasoning is set out on our methodology page.
Left
1 rated outlet
- Common Dreams, the sole left-rated report, led with the headline "'A Match Made in Hell': Former GOP House Leader to Head Big Pharma Lobby." The report highlighted criticism of Cantor's appointment, quoting Peter Maybarduk of Public Citizen who described Cantor as an "experienced reverse Robin Hood." The full report detailed Cantor's voting record against legislation to lower drug prices and noted the approximately $900,000 he received from the industry during his time in Congress. It also mentioned PhRMA's $38 million lobbying expenditure.
Centre
3 rated outlets
- The centre-rated reports from WTVB, STAT, and PR Newswire focused on the announcement of Eric Cantor's appointment as president and CEO of PhRMA. STAT noted that Cantor will face pressure on drug prices and increasing populism. PR Newswire's digest stated that Cantor was named by the Board of Directors of PhRMA. WTVB's digest, similar to regionalmedianews.com, reported the appointment based on information from Reuters.
Right
5 rated outlets
- The right-rated reports from the Washington Times, Breitbart, regionalmedianews.com, The Daily Caller, and thedailybs.com announced Eric Cantor's new role as CEO of PhRMA. The Daily Caller's headline referred to Cantor as "One Of The Biggest Swamp Creatures." Thedailybs.com noted that Cantor will assume the role effective November 9 and mentioned his tenure in the House of Representatives. Regionalmedianews.com and WTVB attributed the announcement to Reuters.
Questions about this coverage
- How did the left and right cover Eric Cantor named president and CEO of PhRMA?
- Of the 9 outlets on this story carrying a published leaning rating, 11% are rated left, 33% are rated centre, 56% are rated right. Those percentages are shares of the rated outlets, not of every outlet that ran it, which was 11. The sections above set out what each side emphasised, in its own terms.
- Is Eric Cantor named president and CEO of PhRMA left or right?
- Too few of the outlets on this story carry a published leaning rating to say. 9 of them do, and this site does not characterise a field under 12: at that size one newsroom filing moves the share by ten points. The percentages above are the count as it stands.
- Is the coverage of Eric Cantor named president and CEO of PhRMA biased?
- Eric Cantor named president and CEO of PhRMA is one event reported by 11 outlets, and this page does not rate the story as biased or unbiased. What it publishes is the spread: which outlets ran it, where named rating organisations place each of them on the spectrum, and what each side chose to lead with. A leaning rating describes an outlet's record over time, not this article, and the two should not be run together.
- Which side is not reporting Eric Cantor named president and CEO of PhRMA?
- When we first saw this story, outlets rated left had barely covered it. Coverage accretes for hours after an event, so that is where to look rather than a verdict — the split above is the current count, and it is the one to read.
- Which outlets covered Eric Cantor named president and CEO of PhRMA?
- 11 that we know of, every one of them listed further up this page with a link to its own report and to what we hold on the publisher. Nothing here is a summary of somebody else's summary: the outlets are named so the original reporting can be read.
- Who is Eric Cantor and what is his new role?
- Eric Cantor is a former US House Majority Leader. He has been named the new president and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), a lobbying group for the pharmaceutical industry.
- How much did PhRMA spend on lobbying?
- According to reports, PhRMA poured $38 million into lobbying efforts. This spending comes amid public pressure to address the affordability of prescription drugs.
- What criticisms have been made about Eric Cantor's past?
- Critics like Peter Maybarduk of Public Citizen have pointed to Cantor's legislative record regarding drug prices, stating he voted against measures to lower costs. During his time in Congress, Cantor received approximately $900,000 from the pharmaceutical and health product industry.
Read it at the source
11 outlets, grouped by the leaning a published rating gives them. Every headline links to the original; an underlined outlet name opens our profile of that publisher.
Left
1Centre
3- US drug lobby group PhRMA names former House leader Cantor as CEO (opens WTVB in a new tab)
- PhRMA taps Eric Cantor as new CEO (opens STAT in a new tab)
- PhRMA Selects Eric Cantor to Lead Organization as Next President and CEO (opens PR Newswire in a new tab)
PR Newswire — is PR Newswire biased? Our profile of this outlet
Right
5- Former House majority leader named CEO of major pharma lobbying group (opens Washington Times in a new tab)
Washington Times — is Washington Times biased? Our profile of this outlet
- Eric Cantor Announced to Serve as President, CEO of PhRMA Organization (opens Breitbart in a new tab)
- US drug lobby group PhRMA names former House leader Cantor as CEO - Regional Media News (opens regionalmedianews.com in a new tab)
regionalmedianews.com — is regionalmedianews.com biased? Our profile of this outlet
- One Of The Biggest Swamp Creatures Takes The Helm Of Drug Lobbying Giant PhRMA (opens The Daily Caller in a new tab)
The Daily Caller — is The Daily Caller biased? Our profile of this outletOpinion
- Eric Cantor takes the helm of drug lobbying Giant Pharma - The Daily Bo Snerdley (opens thedailybs.com in a new tab)
thedailybs.com — is thedailybs.com biased? Our profile of this outlet
Not rated
2How did this read?
About the coverage, not about the story. We do not ask whether you agree with what happened — we have no honest use for that answer.
